Literature DB >> 2888854

L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease.

D R Cooper1, C Marrel, H van de Waterbeemd, B Testa, P Jenner, C D Marsden.   

Abstract

Intraperitoneal administration of the 2-tetrahydropyranylmethyl, phenoxyethyl, ethyl, 2-hydroxypropyl and methyl ester prodrugs of L-dopa produced locomotor activity in reserpine-pretreated mice with equal intensity and duration to that observed following administration of L-dopa itself. Administration of the 2-(1-methoxy)propyl ester produced a more prolonged effect while the p-methoxyphenylethyl, n-propyl, phenylethyl, m-trifluoromethylbenzyl, cyclohexyl, p-chlorophenylethyl and benzyl ester prodrugs were less active than L-dopa itself. On oral administration, the ethyl and methyl ester prodrugs were more effective than L-dopa in reversing reserpine-induced akinesia in mice. The 2-tetrahydropyranylmethyl, 2-(1-methoxy)propyl, 2-hydroxypropyl, n-propyl, benzyl and phenoxyethyl ester prodrugs produced effects comparable with those of L-dopa. In contrast, the cyclohexyl, m-trifluoromethylbenzyl, phenylethyl, p-chlorophenylethyl and p-methoxyphenylethyl ester prodrugs were less effective than L-dopa on oral administration. Intraperitoneal administration of L-dopa and the ester prodrugs of L-dopa to rats with a prior 6-hydroxydopamine (6-OHDA) lesion of the medial forebrain bundle (MFB) produced contraversive circling responses. Rotation observed following administration of the n-propyl, 2-tetrahydropyranylmethyl, methyl and ethyl ester prodrugs was more intense than that observed following administration of L-dopa itself. Rotation produced by the administration of L-dopa and the cyclohexyl, 2-(1-methoxy)propyl, phenylethyl, p-chlorophenylethyl, p-methoxyphenylethyl, benzyl, 2-hydroxypropyl, phenoxyethyl and m-trifluoromethylbenzyl ester prodrugs was identical. Ester prodrugs of L-dopa may be as effective as L-dopa itself in producing motor activity but overall none of the compounds tested was markedly more potent or of longer duration than L-dopa itself.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2888854     DOI: 10.1111/j.2042-7158.1987.tb03441.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  7 in total

1.  Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs.

Authors:  H D Kao; A Traboulsi; S Itoh; L Dittert; A Hussain
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

2.  A comparison of oral and rectal absorption of L-dopa esters in rats and mice.

Authors:  J A Fix; J Alexander; M Cortese; K Engle; P Leppert; A J Repta
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

3.  Short-chain alkyl esters of L-dopa as prodrugs for rectal absorption.

Authors:  J A Fix; J Alexander; M Cortese; K Engle; P Leppert; A J Repta
Journal:  Pharm Res       Date:  1989-06       Impact factor: 4.200

4.  The effect of reserpine treatment in vivo upon L-dopa and amphetamine evoked dopamine and DOPAC efflux in vitro from the corpus striatum of male rats.

Authors:  D E Dluzen; B Liu
Journal:  J Neural Transm Gen Sect       Date:  1994

5.  Novel L-Dopa and dopamine prodrugs containing a 2-phenyl-imidazopyridine moiety.

Authors:  Nunzio Denora; Valentino Laquintana; Angela Lopedota; Mariangela Serra; Laura Dazzi; Giovanni Biggio; Dhananjay Pal; Ashim K Mitra; Andrea Latrofa; Giuseppe Trapani; Gaetano Liso
Journal:  Pharm Res       Date:  2007-04-03       Impact factor: 4.580

Review 6.  Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease.

Authors:  Fatma Haddad; Maryam Sawalha; Yahya Khawaja; Anas Najjar; Rafik Karaman
Journal:  Molecules       Date:  2017-12-25       Impact factor: 4.411

Review 7.  Antiparkinson prodrugs.

Authors:  Antonio Di Stefano; Piera Sozio; Laura Serafina Cerasa
Journal:  Molecules       Date:  2008-01-16       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.